Amolyt Pharma Announces Abstracts Accepted for Presentation at ECE and ENDO
LYON, France and CAMBRIDGE, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has had multiple abstracts accepted for presentation at the 25^th European Congress of Endocrinology (ECE), which is being held May 13-16 in Istanbul, Turkey, and at the 2023 Endocrine Society Meeting (ENDO), which is being held June 15-18 in Chicago, Illinois. These presentations cover both of Amolyt’s development programs, eneboparatide entering Phase 3 for hypoparathyroidism and AZP-3813 entering Phase 1 for acromegaly.Details of the presentations are as follows:
*25*^*th** European Congress of Endocrinology (ECE) – May 13-16, Istanbul, Turkey *
*Title:* Eneboparatide, a Novel PTH-1 Receptor Agonist, Has No Impact on Bone Parameters Following Chronic Treatment of Non-Human Primates
*Format:* Oral Presentation
*Session:* Oral Communications 8: Calcium and Bone
*Date:* Monday, May 15, 2023
*Time:* 2:00-3:00 p.m. CEST
*Title:* Eneboparatide, a Novel PTH-1 Receptor Agonist, Induces Rapid Reduction and Normalization of Urinary Calcium in Chronic Hypoparathyroid Patients
*Format:* Poster / Rapid Oral Presentation
*Session:* Rapid Communications 8: Calcium and Bone
*Date:* Monday, May 15, 2023
*Time:* 3:05-3:40 p.m. CEST
*Poster Display: *9:40 a.m. CEST on Sunday, May 14 – 3:30 p.m. CEST on Tuesday, May 16
*Title:* Treatment of Chronic Hypoparathyroidism by Eneboparatide, a Novel PTH Receptor-1 Agonist: Results from a Phase 2a Study
*Format:* Poster / Rapid Oral Presentation
*Session:* Rapid Communications 8: Calcium and Bone
*Date:* Monday, May 15, 2023
*Time:* 3:05-3:40 p.m. CEST
*Poster Display: *9:40 a.m. CEST on Sunday, May 14 – 3:30 p.m. CEST on Tuesday, May 16
*Title:* AZP-3813, a Bicyclic, 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor, Effectively Suppresses IGF1 in Beagle Dogs
*Format:* Poster / Rapid Oral Presentation
*Session:* Rapid Communication 7: Pituitary and Neuroendocrinology 2
*Date:* Monday, May 15, 2023
*Time: *3:05-3:40 p.m. CEST
*Poster Display: *9:40 a.m. CEST on Sunday, May 14 – 3:30 p.m. CEST on Tuesday, May 16
*2023 Endocrine Society Meeting (ENDO) – June 15-18, Chicago, Illinois*
*Title:* Repeated Treatment with AZP-3813, a Bicyclic, 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor, Induces Enhanced Suppression of IGF1 in Beagle Dogs
*Format:* Poster Presentation
*Session*: Neuroendocrinology: Neuroendocrinology and Pituitary: Growth Hormone and Acromegaly - Basic and Translational
*Date:* Thursday, June 15, 2023
*Time:* 12:30-1:30 p.m. CST
*Poster Display: *9:00 a.m. – 3:00 p.m. CST on Thursday, June 15
*Title:* Treatment of Chronic Hypoparathyroidism with Eneboparatide (AZP-3601), a Novel PTH 1 Receptor Agonist: Results from a Phase 2 Trial
*Format:* Oral Presentation
*Session: *Bone 2 - PTH-Relevant Biology, Pathophysiology, and Therapeutics
*Date:* Saturday, June 17, 2023
*Time:* 9:45-11:15 a.m. CST
*Title:* Variations in Clinical Practice Patterns for Hypoparathyroidism
*Format:* Poster Presentation
*Session: *Bone and Mineral Metabolism: Hypoparathyroidism
*Date:* Saturday, June 17, 2023
*Time:* 1:00-2:00 p.m. CST
*Poster Display: *9:00 a.m. – 3:00 p.m. CST on Saturday, June 17
*Title:* AZP-3601, a Novel PTH 1 Receptor Agonist, Induces Rapid Reduction and Normalization of Urinary Calcium in Chronic Hypoparathyroid Patients
*Format:* Poster Presentation
*Session:* Bone and Mineral Metabolism: Hypoparathyroidism
*Date:* Saturday, June 17, 2023
*Time:* 1:00-2:00 p.m. CST
*Poster Display:* 9:00 a.m. – 3:00 p.m. CST on Saturday, June 17
*About Amolyt Pharma *
Amolyt Pharma, a clinical stage biotechnology company, is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Its development portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. To learn more, visit https://amolytpharma.com/ or follow us on Twitter and LinkedIn.
*Media Inquiries: *
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com
*Investors Inquiries:*
Ashley Robinson
LifeSci Advisors, LLC
arr@lifesciadvisors.com
+1.617.430.7577